Osteoporosis is a disorder of bone mineralization and a significant cause of morbidity and mortality in older individuals.
Risk factors for poor bone mineralization in children and adolescents include:
801-587-7539
801-585-6227
From the hospital entrance- Take the visitor or patient elevators to the 3rd floor of the main hospital building. We are located in the Neuro Acute Care (“NAC”) Unit. Turn right off the elevators, and right down the hall, towards the NAC. The DXA room is across the hall from the nurses station, around the corner from the drinking fountain.
An endocrinologist is a doctor who specializes in the endocrine system. This network of glands inside your body creates hormones that help cells talk to each other. The endocrine system is varied and complex, but one important job it has is to help with reproduction.
A reproductive endocrinologist, sometimes referred to as an RE, is an obstetrician/gynecologist (OB/GYN) physician who diagnoses and treats endocrine disorders that are either directly or indirectly related to reproduction. They largely deal with issues related to infertility, when you’re unable to get pregnant after one year of unprotected sex.
Many people deal with infertility. In fact, up to 15% of couples are infertile, and the issue is just as common among men as it is among women.
Reproductive endocrinologists may use surgery, medicine, or procedures to treat infertility. Before they come up with a treatment plan, they must find the source of the problem. To do this, they might:
Based on the results of these tests, reproductive endocrinologists are better able to make an accurate diagnosis. They may then prescribe medicine or recommend procedures like:
Reproductive endocrinologists also perform various infertility treatments, including:
One full cycle of IVF takes 3 weeks or longer. But it’s the most effective form of assisted reproductive technology to date. Since its introduction in the U.S. in 1981, this procedure and techniques like it have resulted in over 200,000 babies.
The path to becoming a reproductive endocrinologist is a long one. First, you need a bachelor's degree, usually in a science-based field of study.
Like all other physicians, you must then pass the Medical College Admissions Test (MCAT) to get into medical school. Then you’ll attend and graduate from a four-year medical school program.
You’ll then take part in a residency program and get certified as an OB/GYN through the American Board of Obstetrics and Gynecology.
After completing a specialized fellowship in reproductive endocrinology and infertility (REI) after residency, you can take a written and oral exam to become board certified as a reproductive endocrinologist.
You should consider seeing a reproductive endocrinologist if you’re having trouble getting pregnant. As a general guideline, if you’re under 35 and want to conceive a child, you should spend a year trying before you see a reproductive endocrinologist. If you’re over 35, you should try for at least 6 months.
However, you may want to book an appointment with a reproductive endocrinologist if you have any of the following issues:
If you want to get someone pregnant, you should consider seeing a reproductive endocrinologist after a year of regular, unprotected sex or if you have a history of any of the following:
Reproductive endocrinologists are an excellent resource to help you better understand your fertility journey and to provide medical interventions for pregnancy when appropriate.
University of Utah Health offers diabetes management services at multiple locations along the Wasatch Front at our health centers as well as the Utah Diabetes and Endocrinology Center (UDEC). Our goal is to help diabetes patients, by reducing complications and suffering with the end goal of ultimately preventing diabetes.
For patients with other endocrinology disorders, including nodules in the endocrine system, we offer specialty care and individualized treatment plans that focus on the patient’s needs.
The UDEC also provides tailored diabetes education to patients of all ages and is the only facility for comprehensive and continuous diabetes care and management in Utah and the Mountain West region. We are also a research facility consistently researching and applying the newest findings in the field of diabetes management and care.
Medscape Medical News, December 07, 2022
Medscape Medical News, December 07, 2022
MDedge News, December 07, 2022
Reuters Health Information, December 06, 2022
Reuters Health Information, December 06, 2022
Medscape Medical News, December 07, 2022
Medscape Medical News, December 07, 2022
Medscape Medical News, December 07, 2022
First Look, December 07, 2022
Medscape Medical News, December 06, 2022
Medscape Medical News, December 06, 2022
Medscape Medical News, December 06, 2022
Medscape Medical News, December 06, 2022
Medscape Medical News, December 06, 2022
First Look, December 06, 2022
Medscape Medical News, December 05, 2022
Medscape Medical News, December 05, 2022
Medscape Medical News, December 05, 2022
Reuters Health Information, December 03, 2022
Medscape Medical News, December 02, 2022
Researchers have discovered the vital role of a hormone, that develops in men during puberty, in providing an early prediction of whether they could develop certain diseases in later life.
Scientists from the University of Nottingham have discovered that the novel insulin-like peptide hormone, called INSL3, is consistent over long periods of time and is an important early biomarker for prediction of age-linked disease. Their latest findings have been published today in Frontiers in Endocrinology.
INSL3 is made by the same cells in the testes that make testosterone, but unlike testosterone which fluctuates throughout a man's life, INSL3 remains consistent, with the level at puberty remaining largely the same throughout a man's life, decreasing only slightly into old age. This makes it the first clear and reliable predictive biomarker of age-related morbidity as compared to any other measurable parameters.
The results show that the level of INSL3 in blood correlates with a range of age-related illnesses, such as bone weakness, sexual dysfunction, diabetes, and cardiovascular disease.
The discovery of the consistent nature of this hormone is very significant as it means that a man with high INSL3 when young will still have high INSL3 when he is older. But someone with low INSL3 already at a young age, will have low INSL3 when older making him more likely to acquire typical age-related illnesses. This opens up exciting possibilities for predicting age-related illnesses and finding ways to prevent the onset of these diseases with early intervention.
The research was led by Professor Ravinder Anand-Ivell and Professor Richard Ivell and is the latest of three latest studies into this hormone. Professor Ravinder Anand-Ivell explains: "The holy grail of aging research is to reduce the fitness gap that appears as people age. Understanding why some people are more likely to develop disability and disease as they age is vital so that interventions can be found to ensure people not only live a long life but also a healthy life as they age. Our hormone discovery is an important step in understanding this and will pave the way for not only helping people individually but also helping to ease the care crisis we face as a society."
The team analysed blood samples from 3,000 men from 8 regional centres in north, south, east, and west of Europe, including the UK, with two samples taken four years apart. The results showed that unlike testosterone, INSL3 remains at consistent levels in individuals
The study also showed that the normal male population, even when young and relatively healthy, still shows a wide variation between individuals in the concentration of INSL3 in the blood -- almost 10-fold.
Professor Richard Ivell adds: "Now we know the important role this hormone plays in predicting disease and how it varies amongst men we are turning our attention to finding out what factors have the most influence on the level of INSL3 in the blood. Preliminary work suggests early life nutrition may play a role, but many other factors such as genetics or exposure to some environmental endocrine disruptors may play a part."
Story Source:
Materials provided by University of Nottingham. Note: Content may be edited for style and length.
Henry Rodriguez, MD a Professor of Pediatrics, and the Clinical Director USF Diabetes and Endocrinology Center, joined Gayle Guyardo the host of the nationally syndicated health and wellness show Bloom for National Diabetes Month.
You can watch Bloom in the Tampa Bay Market weekdays at 2pm on WFLA News Channel 8.
Bloom also airs in 40 markets across the country, with a reach of approximately 36 million households, and in Puerto Rico, U.S. Virgin Islands and Madison, WI.
People are thankful in all sorts of ways, but Dr. Anupam Kotwal is incredibly grateful. His prognosis is good because the cancer was caught early by the doctor himself. Kotwal was testing a new ultrasound machine, just like he had done in the past. "We were just trying it out on our own necks," Kotwal said. It was one designed to look at deeper parts of the neck to detect abnormalities with a patient's thyroid. When Kotwal put it on his neck, his colleagues looked concerned."My first instinct was, it's probably just a muscle, there's something wrong with the ultrasound machine that we're testing here," Kotwal said. The machine picked up what was a suspicious-looking mass. That night Kotwal got a biopsy, and by the beginning of the next week, he had been diagnosed with stage one thyroid cancer. It was a conversation he was usually on the opposite side of."I've had this conversation innumerable times," Kotwal said. Though, he admits he knew he had to let his doctors do the work. "I had all this knowledge; once the moment I heard it was papillary deferential thyroid cancer, I kind of knew these things, but it was helpful to take a backseat and be the patient," Kotwal said. He was told cancer had spread to his lymph nodes. "Because it had spread from the thyroid, I would have to have surgery to both remove my thyroid gland as well as have a dissection of the left side to remove a lot of the lymph nodes, almost all the lymph nodes that are there," Kotwal said. Now it's been eight months, and Kotwal is sharing his experience to hopefully ease the concern his patients may have after a similar diagnosis."If I see a patient who is going to be very anxious while waiting or after the results, they are very unclear as to what is going to happen," Kotwal said. As a doctor who went from patient back to doctor, Kotwal said he's gained a new perspective. "My outlook on that has changed a little bit," Kotwal said. After his surgery, Kotwal was deemed cancer free.
People are thankful in all sorts of ways, but Dr. Anupam Kotwal is incredibly grateful.
His prognosis is good because the cancer was caught early by the doctor himself. Kotwal was testing a new ultrasound machine, just like he had done in the past.
"We were just trying it out on our own necks," Kotwal said.
It was one designed to look at deeper parts of the neck to detect abnormalities with a patient's thyroid. When Kotwal put it on his neck, his colleagues looked concerned.
"My first instinct was, it's probably just a muscle, there's something wrong with the ultrasound machine that we're testing here," Kotwal said.
The machine picked up what was a suspicious-looking mass.
That night Kotwal got a biopsy, and by the beginning of the next week, he had been diagnosed with stage one thyroid cancer.
It was a conversation he was usually on the opposite side of.
"I've had this conversation innumerable times," Kotwal said.
Though, he admits he knew he had to let his doctors do the work.
"I had all this knowledge; once the moment I heard it was papillary deferential thyroid cancer, I kind of knew these things, but it was helpful to take a backseat and be the patient," Kotwal said.
He was told cancer had spread to his lymph nodes.
"Because it had spread from the thyroid, I would have to have surgery to both remove my thyroid gland as well as have a dissection of the left side to remove a lot of the lymph nodes, almost all the lymph nodes that are there," Kotwal said.
Now it's been eight months, and Kotwal is sharing his experience to hopefully ease the concern his patients may have after a similar diagnosis.
"If I see a patient who is going to be very anxious while waiting or after the results, they are very unclear as to what is going to happen," Kotwal said.
As a doctor who went from patient back to doctor, Kotwal said he's gained a new perspective.
"My outlook on that has changed a little bit," Kotwal said.
After his surgery, Kotwal was deemed cancer free.
image: Michael D. Jensen, MD, FTOS view more
Credit: The Obesity Society
ROCKVILLE, Md.— Michael D. Jensen, MD, FTOS, an endocrinologist with over 35 years of experience in research and practice and past president of The Obesity Society (TOS), is the new editor-in-chief of Obesity, the Society’s flagship, peer-reviewed, scientific journal, the organization announced today.
Associate Editor-in-Chief Leanne Redman, PhD, FTOS, and Managing Editor Allison Templet will remain with the journal as Jensen transitions to his new role.
Jensen explained that his goal is to attract papers that advance the understanding of obesity at all levels, from the basic biology to how the environment contributes to the pre-disposition to or success in treating obesity. The journal’s Impact Factor is 9.298.
“I wish to provide helpful critiques to authors of all submitted manuscripts and keep a short turnaround time. The previous editors did an outstanding job—I feel like I’m coming to bat after Babe Ruth,” said Jensen.
Jensen previously served on the journal’s Editorial Board from 1996–2002 when it was known as Obesity Research. Since 2007, he has served on the Editorial Board under the publication’s current name of Obesity. Jensen was also senior associate editor of the journal Diabetes from 2011–2016.
He has won numerous awards and is a member of multiple associations, in addition to serving on advisory committees. Jensen served as past president of TOS from 2001–2002. In 2019, Jensen was the recipient of the George A. Bray Founders Award. He received the Take off Pounds Sensibly (TOPS) Research Achievement Award from the Society in 2010. Jensen is a member of the Association of American Physicians, American Society for Clinical Investigation, American Diabetes Association, American Society of Nutrition, Endocrine Society among other groups. He served as chair of the Endocrine Society’s Obesity Theme Task Force from 2002–2004. Jensen was the president of Shaping America's Health: Association for Weight Management and Obesity Prevention from 2005–2007.
Former Associate Editor-in-Chief Donna Ryan, MD, observed “it is a great job – editing Obesity means being at the forefront of an area of medicine and science where discoveries are driving better outcomes for patients. Mike is a clinician scientist and ideally suited to lead the journal.”
“Our entire editorial team including Donna Ryan who was my accomplice for more than nine years thanks The Obesity Society for its confidence and support of our leadership of the journal over the past decade,” said outgoing Editor-in-Chief Eric Ravussin, PhD, FTOS. Ravussin will leave his role on Dec. 31, 2022.
Ravussin added “all in all, it has been quite a party with the progress of the journal! I personally extend my best wishes to Mike Jensen who is so qualified to take the leadership of the journal and to even better serve patients with obesity.”
Jensen will start his new role in January 2023.
Reporters and editors interested in interviewing Jensen may contact TOS Director of Communications/Media Relations Chanel Carrington by sending an email request to ccarrington@obesity.org.
# # #
The Obesity Society (TOS) is the leading organization of scientists and health professionals devoted to understanding and reversing the epidemic of obesity and its adverse health, economic and societal effects. Combining the perspective of researchers, clinicians, policymakers and patients, TOS promotes innovative research, education and evidence-based clinical care to Excellerate the health and well-being of all people with obesity. For more information, visit www.obesity.org.
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.
"Best" medical treatment with drugs such as SGLT2 inhibitors and GLP-1 receptor agonists was just as effective as Roux-en-Y gastric bypass at achieving albuminuria remission in patients with diabetic kidney disease and class I obesity. (eClinicalMedicine)
Men with metabolic syndrome, and particularly those with obesity and high triglycerides, had a higher risk for developing gout in a study of almost 1.3 million adult men under age 40. (Arthritis & Rheumatology)
Now that the first-ever type 1 diabetes delaying drug, teplizumab (Tzield), is FDA approved, the next hurdle is getting insurers on board with the $200,000 price tag. (Washington Post)
Typical type 2 diabetes risk factors -- i.e., older age, having overweight or obesity, male sex, non-white race, and tobacco use -- were also risk factors for developing chronic pancreatitis-related diabetes, the PREDICT3c study found. (Diabetes Care)
According to a U.K.-based study using real-world clinical data, researchers determined that using a standard diabetes test to screen all adults between the ages of 40 and 70 would pick up diagnosed type 2 diabetes cases more than 2 years sooner. (Diabetologia)
Gestational diabetes and gestational hypertensive disorder occurring at the same time was linked with a 2.4-fold higher risk for women developing incident cardiovascular disease postpartum. (JAMA Network Open)
"The past 30 years have witnessed tremendous progress in our ability to diagnose and treat osteoporosis ... Despite these remarkable advances, there are crucial clinical practice and scientific gaps in fracture prevention in the USA," researchers wrote in The Lancet Diabetes & Endocrinology.
Among hospitalized patients, death due to Candida bloodstream infections was much more common in patients with diabetes in a 10-year study. (Royal College of Physicians of Edinburgh)